ACL InjuryNCT06571955
ACL Reconstruction with a New Generation of LARS Artificial Ligament
A study testing Implantation of LARS artificial grafted ligament to treat ACL injury and Implantation of LARS artificial non-grafted ligament to treat ACL injury in people with ACL Injury, run by MOVMEDIX at 1 site in Italy.
Trial summary
This clinical investigation is intended to demonstrate the safety of the new generation of LARS ligaments and compare this new generation (grafted ligament) of artificial ligament to the LARS current artificial ligament (non-grafted ligament) which is CE marked since 1997, in case of ACL injury. Read more about this study
- Who is it for?
- Ages 41 years and older
- Conditions the study is for
- ACL Injury
- What is being tested?
- Implantation of LARS artificial grafted ligament to treat ACL injury and Implantation of LARS artificial non-grafted ligament to treat ACL injury
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteItaly
- Study dates
- 22 Dec 2021to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 41 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the grafted ligament
- Subject provides written informed consent approved by the Ethics Committee prior to any clinical investigation related procedure
- Subject must agree to undergo all clinical investigation plan - required clinical follow-up visits
- Subject must agree not to participate in any other clinical investigation for a period of 1 year following the procedure
- Male and female subjects over 40 years old
- MRI positive for full acute ACL injury
Show all 10Show fewer
- Arthrometric evaluation (KT1000) with a side-to-side difference greater than 3 mm
- Symptomatic subjects with no previous knee injury
- Subjects without concomitant pathologies (fracture, infections, immunodepression, HIV, HCV) that could influence the outcome of the study or prevent the subject from following the post-operative follow-up program as per protocol
- I and II degree chondral lesions
Who cannot join
- Subjects under 40 years old
- III and IV degree chondral lesions
- Associated ligament injuries
- Meniscus suture (e.g. hndle bucket meniscal tears) that compromise the rehabilitation program
- History for sepsis
- Subjects with concomitant pathologies (fracture, infections, immunodepression, HIV, HCV,) that could influence the outcome of the study or prevent the subject from following the post-operative follow-up program as per protocol
Show all 18Show fewer
- Previous knee injuries
- Septic arthritis
- Infected tissues
- Pregnancy
- Overweighed, obese subject (>100kg)
- History of metabolic bone disease
- Inflammatory joint disease
- Known neoplastic disease
- Medical treatment (e.g steroid)
- HIV positive subject
- Hepatitis positive subject
- Allergy to Titanium, PET, Ugurol, Gentamicin, Polystyrene Sulfonate, other medication
Trial locations and contacts
1 site in 1 country.
Italy1 site
Instituto di Ricerca Traslazionale Per l'Apparato Locomotore Nicola Cerulli (I.R.T.A.L)
Perugia, 06100
About this study
Official title: Anterior Cruciate Ligament (ACL) Reconstruction with a New Generation of LARS Artificial Ligament
This clinical investigation is intended to demonstrate the safety of the new generation of LARS ligaments and compare this new generation (grafted ligament) of artificial ligament to the LARS current artificial ligament (non-grafted ligament) which is CE marked since 1997, in case of ACL injury. The new generation of LARS artificial ligament is expected to improve physiological response by enhancing fibroblast proliferation, fibroblast organization and collagen type I \& III secretion. This physiological response leads to a better osseo-integration of the ligaments. Therefore, the study is expected to demonstrate the investigational device safety and biomechanical improvements.
Read the detailed description
Forty subjects over 40 years old with acute ACL injury will be included. A follow-up program is planned over 1 year per subject (days 7, 15, 30, 60, 90, 180, 365) based on physical therapy, biological analysis and biomechanical measurements.
- Conditions
- ACL Injury
- Being tested
- Implantation of LARS artificial grafted ligament to treat ACL injury, Implantation of LARS artificial non-grafted ligament to treat ACL injury
- Keywords
- ACL, Artificial ligament
- Medical subject headings
- Anterior Cruciate Ligament Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implantation of LARS artificial grafted ligament to treat ACL injuryDevice
Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
Implantation of LARS artificial non-grafted ligament to treat ACL injuryDevice
Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
| Study group | Role | What they receive |
|---|---|---|
| LARS grafted | Experimental | Patients implanted with grafted ligament (new generation) Receives: Device: Implantation of LARS artificial grafted ligament to treat ACL injury |
| Control | Active comparator | Patients implanted with non-grafted ligament (current generation) Receives: Device: Implantation of LARS artificial non-grafted ligament to treat ACL injury |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Serious Adverse Device Effect (SADE)
Primary outcome will evaluate the safety of the grafted ligament by reporting the number of SADE(s) in the Experimental Arm.
Measured: 6 months
Secondary outcomes (6)
Assessment of patients' opinion about their knee and associated problems
Patient will answer the questionnaire KOOS (Knee Injury and Osteoarthritis Outcome Score) pre-surgery, 90, 180 and 365 days post-surgery.
This is a knee-specific instrument, developed to assess the patients' opinion about their knee and associated problems both on short-term and long-term. The KOOS questionnaire includes five dimensions that are relevant to patients: pain, symptoms, daily activities, sports and recreation, and quality of life. Each of these dimensions is scored separately, using a Likert scale with five possible answers ranging from 0 (no problems) to 4 (extreme problems). The scores for each dimension are calculated by summing the answers to the relevant questions. The resulting scores are then transformed to a scale from 0 to 100, with 0 representing extreme knee problems and 100 representing no knee problems. Answers to the questionnaire pre-surgery will be compared to the answers collected at 90, 180 and 365 days post-surgery.
Measured: 12 months
Assessment of patients' pain intensity
The Visual Analogue Scale (VAS) will be used to measure the intensity or frequency of various symptoms, most commonly pain. Patients will be asked to mark a point on the line that represents their perception of their current state pre-surgery, 90, 180 and 365 days post-surgery. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Scores obtained pre-surgery will be compared to the scores obtained at 90, 180 and 365 days post-surgery.
Measured: 12 months
Assessment of overall knee function
The IKDC Subjective Knee Evaluation Form is used to evaluate the knee. The questionnaire looks at 3 categories: symptoms, sports activity and knee function. The symptoms subscale helps to evaluate things such as pain, stiffness, swelling and giving-way of the knee. The sports activity subscale focuses on functions such as; going up and down the stairs, rising from a chair, squatting and jumping. The knee function subscale asks patients 1 simple question - how is their knee at present versus how was their knee prior to injury.
Scores are obtained by summing the individual items and then transforming the crude total to a scaled number that ranges from 0 to 100. Higher scores indicate higher levels of function and lower levels of symptoms. Patients will complete the IKDC form pre-surgery, 90, 180 and 365 days post-surgery. Scores obtained pre-surgery will be compared to the scores obtained at 90, 180 and 365 days post-surgery.
Measured: 12 months
Assessment of posterior-anterior knee laxity
Posterior-anterior knee laxity is measured using a KT-1000 arthrometer. The subject lies in a supine position with the knee flexed about 20°, a support is placed below the knee proximal to the popliteal space. The subject is told to relax in this position. The arthrometer is then placed above the tibia and attached firmly by two bands. After adjusting the zero, the tibia is pulled anteriorly using the handle on the arthrometer. An audible indication will be noticed at 15, 20 and 30 pounds (approx. 6, 9 and 13kg) of force. Moreover, a manual maximum measure is performed pulling the tibia with a hand on the back of the shank, until the foot is raised. Displacement is measured in millimeters and compared with the healthy leg measurements. The difference between the legs should be 1mm - 15mm.
Knee laxity will be measured pre-surgery, 45, 90, 180 and 365 days post-surgery. Values at pre-surgery will be compared to the ones from post-surgery mesurements.
Measured: 12 months
Assessment of knee flexors-extensors strength
Knee flexors-extensors strength assessment will be measured using an Isokinetic machine and superficial EMG evaluation. The subject performs an isokinetic concentric evaluation with a fixed velocity of 90°/s with a range of motion of 0-90° of knee flexion. After warming-up, subject is asked to sit on the resting chair of the dynamometer, the subject is then secured with body straps. The starting position is 90° flexion for the knee and 90° for the hip joint. The subject is instructed to extend the knee till 0° flexion and then to flex the knee back at 90° with maximum exertion. The test is performed firstly on the healthy side and then on the injured side. Peak forces are compared between the legs.
Knee flexors-extensors strength will be measured pre-surgery, 90, 180 and 365 days post-surgery. Values at pre-surgery will be compared to the ones from post-surgery mesurements.
Measured: 12 months
Assessment of stabilometry
The subject is asked to stay still on a force platform for 10 seconds, firstly standing only on one leg with the arms folded across the chest. The test is then repeated on the other leg. The motion/change of the centre of pressure is used to quantify ellipse area to measure stability. Usually, ellipse area results for stabilometry test show differences between the healthy and the injured leg.
Stabilometry will be measured in both legs pre-surgery, 45, 90, 180 and 365 days post-surgery.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2024
- Study start22 Dec 2021
- Primary completion28 Mar 2024
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ACL InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- MOVMEDIX
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Guliano Cerulli, MD, Principal investigator, Instituto di Ricerca Traslazionale Per l'Apparato Locomotore Nicola Cerulli (I.R.T.A.L)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06571955
- Sponsor's protocol ID
- CD/PT.03
- Status last verified
- Oct 2024
- First submitted
- 15 Jul 2024
- Last updated
- 21 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anterior Cruciate Ligament (ACL) Reconstruction with a New Generation of LARS Artificial Ligament
- ClinicalTrials.gov ID
- NCT06571955
- Acronym / sponsor ID
- CD/PT.03
- Conditions
- ACL Injury
- Keywords
- ACL, Artificial ligament
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (actual)
- Lead sponsor
- MOVMEDIXIndustry (pharma, biotech, devices)
- Study start
- 22 Dec 2021 (actual)
- Primary completion
- 28 Mar 2024 (actual)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 26 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical investigation is intended to demonstrate the safety of the new generation of LARS ligaments and compare this new generation (grafted ligament) of artificial ligament to the LARS current artificial ligament (non-grafted ligament) which is CE marked since 1997, in case of ACL injury. The new generation of LARS artificial ligament is expected to improve physiological response by enhancing fibroblast proliferation, fibroblast organization and collagen type I \& III secretion. This physiological response leads to a better osseo-integration of the ligaments. Therefore, the study is expected to demonstrate the investigational device safety and biomechanical improvements.
Detailed description
Forty subjects over 40 years old with acute ACL injury will be included. A follow-up program is planned over 1 year per subject (days 7, 15, 30, 60, 90, 180, 365) based on physical therapy, biological analysis and biomechanical measurements.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LARS grafted | Experimental | Device: Implantation of LARS artificial grafted ligament to treat ACL injuryPatients implanted with grafted ligament (new generation) |
| Control | Active comparator | Device: Implantation of LARS artificial non-grafted ligament to treat ACL injuryPatients implanted with non-grafted ligament (current generation) |
Who may qualify
- Ages
- 41 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the grafted ligament
- Subject provides written informed consent approved by the Ethics Committee prior to any clinical investigation related procedure
- Subject must agree to undergo all clinical investigation plan - required clinical follow-up visits
- Subject must agree not to participate in any other clinical investigation for a period of 1 year following the procedure
- Male and female subjects over 40 years old
Key exclusion criteria (18 listed)
- Subjects under 40 years old
- III and IV degree chondral lesions
- Associated ligament injuries
- Meniscus suture (e.g. hndle bucket meniscal tears) that compromise the rehabilitation program
- History for sepsis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implantation of LARS artificial grafted ligament to treat ACL injuryImplantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament. | Device | LARS grafted |
| Implantation of LARS artificial non-grafted ligament to treat ACL injuryImplantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments. | Device | Control |
Primary outcome
Incidence of Serious Adverse Device Effect (SADE)
Time frame: 6 months
Primary outcome will evaluate the safety of the grafted ligament by reporting the number of SADE(s) in the Experimental Arm.
6 secondary outcomes
Assessment of patients' opinion about their knee and associated problems
Time frame: 12 months
Assessment of patients' pain intensity
Time frame: 12 months
Assessment of overall knee function
Time frame: 12 months
Assessment of posterior-anterior knee laxity
Time frame: 12 months
Assessment of knee flexors-extensors strength
Time frame: 12 months
Assessment of stabilometry
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2024.
- Individual participant dataSharing planned: No
Related trials for ACL Injury
Not yet recruiting
Stair Biomechanics and Vibration Study After ACLR
Anterior Cruciate Ligament Reconstruction (ACLR), Anterior Cruciate Ligament Injury
Not yet recruiting
Supporting Athletes' Return to Sports After ACL Reconstruction: A Study of a Psychological Readiness Program
Anterior Cruciate Ligament Reconstruction, Anterior Cruciate Ligament Injuries
Recruiting
Graded Exposure and Mindfulness Meditation for Patients Post-ACL Reconstruction
Anterior Cruciate Ligament Injuries
Not yet recruiting
Clinical and Biological Outcomes of BioBrace-Augmented ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Not yet recruiting
Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Postoperative Recovery Quality in Patients Undergoing Anterior Cruciate Ligament Reconstruction
Anterior Cruciate Ligament Injuries, Recovery Quality
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Guliano Cerulli, MD principal investigator
Instituto di Ricerca Traslazionale Per l'Apparato Locomotore Nicola Cerulli (I.R.T.A.L)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Implantation of LARS artificial grafted ligament to treat ACL injury and Implantation of LARS artificial non-grafted ligament to treat ACL injury in people with ACL Injury, run by MOVMEDIX at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Serious Adverse Device Effect (SADE) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2024.